{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:23:45Z","timestamp":1783128225394,"version":"3.54.6"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>The mandatory 6-mo waiting period implemented in 2015 for accruing model for end-stage liver disease exception points in patients with early-stage hepatocellular carcinoma (HCC) awaiting orthotopic liver transplantation (OLT) has been associated with improved outcomes. However, most of these findings are dependent on cohorts who have had access to the OLT waitlist, and the policy\u2019s impact on non-OLT treatment strategies (eg, liver resection, ablation) remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>This was a retrospective analysis of patients with early-stage HCC (T2N0M0) from the National Cancer Database from 2010 to 2021. The pre-\/post-policy era was defined by HCC diagnosis before or after 2015, respectively. The Kaplan-Meier survival method and multivariable Cox proportional hazard regression were used to estimate survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Among 53\u2009928 patients, rates of OLT decreased (13.1%\u20137.4%), ablation increased (19.1%\u201325.3%), and resection remained constant (9.2% versus 9.2%) from the pre- to post-policy era (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001 for all). OLT was associated with the highest 5-y postoperative survival (79.7%), followed by resection (63.5%) and ablation (42.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001, all pairwise comparisons). Overall survival improved in the post-policy era (hazard ratio, 0.89; 95% confidence interval, 0.87-0.92), with resection having the greatest improvement in survival (hazard ratio, 0.69; 95% confidence interval, 0.62-0.77). Among all treatment modalities, time-to-intervention was not a predictor of mortality (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u20050.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Overall, the post-policy era was associated with improved outcomes in early-stage HCC. While survival outcomes between policy eras were similar for OLT or ablation, liver resection was shown to have the highest improvement in survival and remains a durable treatment option in early-stage HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005536","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:08:08Z","timestamp":1760375288000},"page":"e204-e216","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis"],"prefix":"10.1097","volume":"110","author":[{"given":"Bima J.","family":"Hasjim","sequence":"first","affiliation":[{"name":"Department of Surgery, University of California, Irvine, Orange, CA."},{"name":"Transplant AI initiative, Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Paukner","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA."},{"name":"Stanford Transplant Outcomes Research Center, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[{"name":"Transplant AI initiative, Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, ON, Canada."},{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada."},{"name":"Division of Gastroenterology & Hepatology, Department of Medicine, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Ichii","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplant Surgery, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Transplant Surgery, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljka","family":"Jutric","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Imagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed I.","family":"Ayabe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, University of California, Irvine, Orange, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"R1-20260119","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20260119","doi-asserted-by":"crossref","first-page":"e0298887","DOI":"10.1371\/journal.pone.0298887","article-title":"Increasing prevalence of cirrhosis among insured adults in the United States, 2012\u20132018.","volume":"19","author":"Ladner","year":"2024","journal-title":"PLoS One"},{"key":"R3-20260119","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"key":"R4-20260119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.surg.2017.12.005","article-title":"Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.","volume":"163","author":"Benjamin","year":"2018","journal-title":"Surgery"},{"key":"R5-20260119","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20260119","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to surgery and breast cancer survival in the United States.","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncology"},{"key":"R7-20260119","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.6004\/jnccn.2013.0131","article-title":"Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma.","volume":"11","author":"Singal","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20260119","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/bjc.2015.48","article-title":"Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.","volume":"112","author":"Neal","year":"2015","journal-title":"Br J Cancer"},{"key":"R9-20260119","doi-asserted-by":"crossref","first-page":"e0199532","DOI":"10.1371\/journal.pone.0199532","article-title":"Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer.","volume":"13","author":"Tsai","year":"2018","journal-title":"PLoS One"},{"key":"R10-20260119","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/TP.0000000000001752","article-title":"Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time \u201csweet spot.\u201d","volume":"101","author":"Mehta","year":"2017","journal-title":"Transplantation"},{"key":"R11-20260119","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/hep.27704","article-title":"Delayed hepatocellular carcinoma model for end\u2010stage liver disease exception score improves disparity in access to liver transplant in the United States.","volume":"61","author":"Heimbach","year":"2015","journal-title":"Hepatology"},{"key":"R12-20260119","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/TP.0000000000004860","article-title":"Significant reduction in posttransplant hepatocellular carcinoma recurrence in the post 6-mo waiting policy era.","volume":"108","author":"Mahmud","year":"2023","journal-title":"Transplantation"},{"key":"R13-20260119","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States.","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20260119","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1053\/j.gastro.2018.07.025","article-title":"Effects of allocating livers for transplantation based on model for end-stage liver disease\u2013sodium scores on patient outcomes.","volume":"155","author":"Nagai","year":"2018","journal-title":"Gastroenterology"},{"key":"R15-20260119","doi-asserted-by":"crossref","first-page":"55","DOI":"10.35772\/ghm.2019.01029","article-title":"Long-term outcomes in patients undergoing resection, ablation, and trans-arterial chemoembolization of hepatocellular carcinoma in the United States: a National Cancer Database analysis.","volume":"1","author":"Kawaguchi","year":"2019","journal-title":"Global Health & Medicine"},{"key":"R16-20260119","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2967\/jnumed.121.261954","article-title":"Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: analysis of the U.S. National Cancer Database.","volume":"62","author":"Ahn","year":"2021","journal-title":"J Nuclear Med"},{"key":"R17-20260119","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis.","volume":"41","author":"Dunn","year":"2005","journal-title":"Hepatology"},{"key":"R18-20260119","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jhep.2017.09.017","article-title":"Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma.","volume":"68","author":"Lim","year":"2018","journal-title":"J Hepatol"},{"key":"R19-20260119","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jamcollsurg.2016.01.046","article-title":"Time-to-surgery and survival outcomes in resectable colorectal liver metastases: a multi-institutional evaluation.","volume":"222","author":"Leal","year":"2016","journal-title":"J Am Coll Surg"},{"key":"R20-20260119","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamasurg.2022.3327","article-title":"Survival benefit of living-donor liver transplant.","volume":"157","author":"Jackson","year":"2022","journal-title":"JAMA Surgery"},{"key":"R21-20260119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00268-022-06732-5","article-title":"Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations 2022.","volume":"47","author":"Joliat","year":"2023","journal-title":"World J Surg"},{"key":"R22-20260119","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4254\/wjh.v14.i5.885","article-title":"Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma.","volume":"14","author":"Zane","year":"2022","journal-title":"World J Hepatol"},{"key":"R23-20260119","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/bjs.8915","article-title":"Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria.","volume":"99","author":"Lim","year":"2012","journal-title":"Br J Surg"},{"key":"R24-20260119","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.gastro.2015.05.025","article-title":"Comparison of liver transplant-related survival benefit in patients with versus without hepatocellular carcinoma in the United States.","volume":"149","author":"Berry","year":"2015","journal-title":"Gastroenterology"},{"key":"R25-20260119","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.cgh.2019.07.051","article-title":"Perioperative evaluation and management of patients with cirrhosis: risk assessment, surgical outcomes, and future directions.","volume":"18","author":"Newman","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20260119","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/LVT.0000000000000229","article-title":"Policy corner: HCC exception update.","volume":"29","author":"Mehta","year":"2023","journal-title":"Liver Transpl"},{"key":"R27-20260119","doi-asserted-by":"crossref","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.","volume":"10","author":"Xia","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R28-20260119","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/HEP.0000000000000726","article-title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.","volume":"82","author":"Vogel","year":"2023","journal-title":"Hepatology"},{"key":"R29-20260119","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R30-20260119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R31-20260119","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity.","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Cancer"},{"key":"R32-20260119","first-page":"779","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma.","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surgery"},{"key":"R33-20260119","doi-asserted-by":"crossref","first-page":"101246","DOI":"10.1016\/j.jhepr.2024.101246","article-title":"Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma.","volume":"7","author":"Tabrizian","year":"2025","journal-title":"JHEP Reports"},{"key":"R34-20260119","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jamcollsurg.2013.07.007","article-title":"Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study.","volume":"217","author":"Hyder","year":"2013","journal-title":"J Am Coll Surg"},{"key":"R35-20260119","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajt.2023.03.012","article-title":"Stakeholders\u2019 perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients\u2019 consensus conference.","volume":"23","author":"Snyder","year":"2023","journal-title":"Am J Transplant"},{"key":"R36-20260119","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.surg.2024.08.020","article-title":"Racial disparities in access to liver transplantation in patients with early-stage hepatocellular carcinoma.","volume":"176","author":"Orozco","year":"2024","journal-title":"Surgery"},{"key":"R37-20260119","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00268-023-06969-8","article-title":"Disparities in the receipt of recommended curative treatment for patients with early-stage hepatocellular carcinoma.","volume":"47","author":"Rasic","year":"2023","journal-title":"World J Surg"},{"key":"R38-20260119","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jss.2022.05.035","article-title":"Inferior survival is associated with socioeconomic deprivation in hepatocellular carcinoma.","volume":"279","author":"Ruffolo","year":"2022","journal-title":"J Surg Res"},{"key":"R39-20260119","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.hpb.2021.10.023","article-title":"Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma.","volume":"24","author":"Sugumar","year":"2022","journal-title":"HPB"},{"key":"R40-20260119","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1477-2574.2012.00496.x","article-title":"Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.","volume":"14","author":"Visser","year":"2012","journal-title":"HPB"},{"key":"R41-20260119","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ajt.2024.02.009","article-title":"Where you live matters: area deprivation predicts poor survival and liver transplant waitlisting.","volume":"24","author":"Hasjim","year":"2024","journal-title":"Am J Transplant"},{"key":"R42-20260119","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.14309\/ajg.0000000000003171","article-title":"Social disadvantage and disparities in chronic liver disease: a systematic review.","volume":"120","author":"Hasjim","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R43-20260119","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1097\/LVT.0000000000000423","article-title":"Letter to the editor: adopting a \u201ccancer model\u201d of referral to achieve equity in access to liver transplantation.","volume":"30","author":"Tavabie","year":"2024","journal-title":"Liver Transpl"},{"key":"R44-20260119","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/LVT.0000000000000444","article-title":"PRO: how satellite clinics can improve access to liver transplantation.","volume":"30","author":"Hughes","year":"2024","journal-title":"Liver Transplant"},{"key":"R45-20260119","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/hep.30074","article-title":"Virtual consultations through the veterans administration SCAN\u2010ECHO project improves survival for veterans with liver disease.","volume":"68","author":"Su","year":"2018","journal-title":"Hepatology"},{"key":"R46-20260119","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/LVT.0000000000000442","article-title":"Satellite clinics are a marketing tool and do not improve access and equity in liver transplantation.","volume":"30","author":"Bittermann","year":"2024","journal-title":"Liver Transpl"},{"key":"R47-20260119","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/flgastro-2022-102366","article-title":"Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study.","volume":"14","author":"Tavabie","year":"2023","journal-title":"Front Gastroenterol"},{"key":"R49-20260119","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.31742","article-title":"Black patients with cirrhosis have higher mortality and lower transplant rates: results from a metropolitan cohort study.","volume":"74","author":"Mazumder","year":"2021","journal-title":"Hepatology"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:00:13Z","timestamp":1768834813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005536","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}